Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to ... Read More
Pfizer to manufacture Gilead’s Covid-19 drug candidate remdesivir
Pfizer has signed a multi-year agreement with Gilead Sciences to manufacture and supply the latter's investigational antiviral remdesivir for the treatment of Covid-19. Under the ... Read More
Gilead Sciences announces Veklury EU approval for COVID-19 treatment
Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 ... Read More
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics
Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also ... Read More
Gilead Covid-19 drug candidate remdesivir delivers desired results in phase 3 trial
Remdesivir clinical trial results : Gilead Sciences said that the phase 3 SIMPLE trial, which has been evaluating the Covid-19 drug candidate remdesivir for the ... Read More
FDA grants EUA for Gilead’s investigational COVID-19 drug remdesivir
Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus with the Food and Drug Administration (FDA) ... Read More
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven
Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been ... Read More
Gilead Sciences, Second Genome form IBD drug discovery alliance
Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates ... Read More
Gilead Sciences bags Epclusa FDA approval for hepatitis C in pediatric patients
Epclusa FDA approval : Gilead Sciences has secured an expanded approval for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) from the US Food and ... Read More
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More